olivLaw · US equity research
Spectral AI, Inc. MDAI
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
Spectral AI is an artificial intelligence company developing the DeepView System, a predictive diagnostic tool for wound healing with a focus on burns. Following FDA De Novo classification in May 2026, the company is preparing for its first commercial sales, while its current revenue comes almost entirely from U.S. government contracts and research revenue has declined, making the transition to commercialization decisive. Guidance for 2026 points to revenue of about 18.5 million USD.
At the close of 05 Nov 2026, Spectral AI, Inc. (MDAI) stock was 1.38 USD (−9.80% on the day), with market capitalisation 44.4 m USD, beta 1.37, 52-week range 1.20–2.68 USD. Latest reported quarter (Q2 2026): revenue of 3.5 m USD (−30.4% YoY), net income of -4.2 m USD, diluted EPS -0.13 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 32.6
- weak (30–45)
- Bollinger (20, 2)
- 1.42 – 1.63
- below the lower band · %B -0.18 · band width 14.0%
- SMA 50 / 200
- 1.57 / 1.70
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.03 / -0.02
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −16.9% | −5.9% | −10.9 pp | — |
| 3 months | −16.9% | −4.6% | −12.2 pp | — |
| 6 months | −38.7% | +0.2% | −38.9 pp | — |
| Year to date | −2.8% | +7.4% | −10.2 pp | — |
| 1 year | −29.9% | +8.2% | −38.2 pp | +0.7% |
| 3 years | −53.4% | +68.4% | −121.8 pp | −11.8% |
| 5 years | −85.8% | +56.5% | −142.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.2 m | 7.6 m | 6.7 m | 5.1 m | 3.8 m | 4.1 m | 4.0 m | 3.5 m |
| Cost of revenue | 4.5 m | 4.3 m | 3.5 m | 2.8 m | 2.2 m | 2.2 m | 2.0 m | 2.4 m |
| Gross profit | 3.7 m | 3.3 m | 3.2 m | 2.3 m | 1.6 m | 1.8 m | 2.0 m | 1.1 m |
| Research & development | — | — | 3.6 m | 1.5 m | 6.2 m ≈ | — | 2.0 m | 1.7 m |
| Operating income | -886.0 k | -1.1 m | -896.0 k | -2.1 m | -3.3 m | -2.2 m | -2.0 m | -4.3 m |
| Interest expense | 8.0 k | — | 20.0 k | 120.0 k | 300.0 k | 289.0 k | 258.0 k | 378.0 k |
| Pre-tax income | -1.5 m | -7.6 m | 3.0 m | -8.0 m | -3.6 m | 1.0 m | -3.4 m | -4.0 m |
| Income tax | 37.0 k | -14.0 k | 71.0 k | -19.0 k | 2.0 k | -43.0 k | -10.0 k | 170.0 k |
| Net income | -1.5 m | -7.6 m | 2.9 m | -8.0 m | -3.6 m | 1.1 m | -3.4 m | -4.2 m |
| Diluted EPS | -0.08 | -0.39 ≈ | 0.11 | -0.31 | -0.13 | 0.03 ≈ | -0.11 | -0.13 |
| Operating cash flow | -1.6 m ≈ | 469.0 k | -1.5 m | -3.4 m ≈ | -2.5 m ≈ | -2.6 m | -3.7 m | -4.1 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | unavailable | 25.4 m | 18.1 m | 29.6 m | 19.7 m |
| Revenue YoY | unavailable | unavailable | −28.8% | +63.8% | −33.6% |
| Net income | -2.1 m | -2.9 m | -20.9 m | -15.2 m | -7.6 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.22 | -1.48 | -0.85 | -0.29 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | -11.5% | -115.5% | -51.2% | -38.5% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 15.4 m USD
- Financial debt
- 5.5 m USD
- Net debt
- -9.9 m USD
- Equity
- -5.7 m USD
- Total assets
- 21.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.94x
- ROE
- unavailable
- ROA
- -45.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Revenue | — | 25.4 m | 18.1 m | 29.6 m | 19.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Cost of revenue | — | 14.5 m | 10.2 m | 16.3 m | 10.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Gross profit | — | 10.8 m | 7.9 m | 13.3 m | 8.9 m | SEC (XBRL)· 25 Mar 2026verified |
| Research & development | — | 16.5 m | 15.1 m | — | — | SEC (XBRL)· 29 Mar 2024verified |
| Operating income | -3.4 m | -2.6 m | -13.0 m | -6.6 m | -8.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Interest expense | — | — | — | -14.0 k | 886.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Pre-tax income | -2.1 m | -2.8 m | -20.8 m | -15.0 m | -7.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Income tax | 0 | 106.0 k | 11.0 k | 114.0 k | 11.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Net income | -2.1 m | -2.9 m | -20.9 m | -15.2 m | -7.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Diluted EPS | — | -0.22 | -1.48 | -0.85 | -0.29 | SEC (XBRL)· 25 Mar 2026verified |
| Weighted average diluted shares | — | 13.1 m | 14.1 m | 17.9 m | 26.5 m | SEC (XBRL)· 25 Mar 2026verified |
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Cash | 769.4 k | 14.2 m | 4.8 m | 5.2 m | 15.4 m | SEC (XBRL)· 25 Mar 2026verified |
| Receivables | — | 2.3 m | 2.3 m | 2.5 m | 1.3 m | SEC (XBRL)· 25 Mar 2026verified |
| Inventories | — | — | 230.0 k | 425.0 k | 838.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Current assets | 1.1 m | 17.7 m | 9.9 m | 10.1 m | 19.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Property, plant & equipment, net | — | 21.0 k | 12.0 k | 2.0 k | 258.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Total assets | 254.1 m | 18.7 m | 10.7 m | 12.1 m | 21.4 m | SEC (XBRL)· 25 Mar 2026verified |
| Accounts payable | — | 2.8 m | 2.7 m | 4.0 m | 3.0 m | SEC (XBRL)· 25 Mar 2026verified |
| Long-term debt | — | — | — | 2.8 m | 5.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Current liabilities | 2.9 m | 6.4 m | 12.4 m | 17.6 m | 20.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Total liabilities | 21.9 m | 6.7 m | 12.4 m | 19.3 m | 27.1 m | SEC (XBRL)· 25 Mar 2026verified |
| Equity | 13.8 m † | 12.0 m † | -2.1 m † | -7.3 m † | -5.7 m † | SEC (XBRL)· 25 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Operating cash flow | -825.6 k | -1.2 m | -13.2 m | -9.2 m | -9.9 m | SEC (XBRL)· 25 Mar 2026verified |
| Investing cash flow | -253.0 m | 251.6 m | — | — | — | SEC (XBRL)· 31 Mar 2023verified |
| Financing cash flow | 254.6 m | -785.0 k | 3.8 m | 9.6 m | 20.1 m | SEC (XBRL)· 25 Mar 2026verified |
| Share repurchases | 0 | 250.5 m | — | — | — | SEC (XBRL)· 31 Mar 2023verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 44.4 m USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -65.5% | 25 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -8.2% | 0 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -9.7x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 0.9x | 8 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet3/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial25/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SPECTRAL AI, INC. (MDAI). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 19.6 m USD in 2025; YoY growth -33.6%; net margin -65.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -65.5%
- Revenue CAGR 3Y: -8.2%
- Interest coverage: -9.7x
- Current ratio: 0.9x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 127.6 bn | 35.7 | 16.0% | 13.8% | +11.2% | −10% / +13% |
| MMM3m Company | 97.0 bn | 28.0 | 80.8% | 14.0% | +1.5% | +9% / +127% |
| BSXBoston Scientific Corporation | 64.7 bn | 18.9 | 14.3% | 16.6% | +19.9% | −56% / −20% |
| BDXBecton, Dickinson And Company | 58.2 bn | 64.5 | 3.8% | 4.0% | +8.2% | +40% / +15% |
| RMDResMed Inc. | 33.7 bn | 21.8 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 31.5 bn | 33.3 | 37.7% | 19.4% | +15.6% | +33% / −27% |
| WSTWest Pharmaceutical Services, Inc. | 27.3 bn | 44.1 | 21.2% | 18.8% | +6.3% | +42% / +12% |
| SOLVSolventum Corporation | 14.8 bn | 98.2 | 3.2% | 1.9% | +0.9% | +2% / unavailable |
| PENPenumbra, Inc | 12.7 bn | 80.9 | 10.7% | 10.1% | +17.5% | +10% / +45% |
| GMEDGlobus Medical, Inc. | 10.9 bn | 20.0 | 12.1% | 17.8% | +16.7% | −11% / +81% |
| TFXTeleflex Incorporated | 6.0 bn | 18.5 | 8.3% | 13.5% | +17.2% | +33% / −33% |
| MMSIMerit Medical Systems Inc | 5.4 bn | 33.7 | 9.8% | 9.9% | +11.8% | +3% / +25% |
| ATRCAtriCure, Inc. | 3.1 bn | 206.6 | 2.9% | 2.5% | +14.9% | +70% / +73% |
| LMATLemaitre Vascular, Inc. | 1.9 bn | 30.4 | 15.6% | 23.5% | +13.5% | +1% / +58% |
| NVCRNovoCure Limited | 1.6 bn | — | -35.2% | -16.8% | +8.3% | +6% / +10% |
| KIDSOrthoPediatrics Corp | 841.3 m | — | -9.8% | -12.8% | +15.4% | +74% / +5% |
| TCMDTactile Systems Technology, Inc. | 590.7 m | 25.7 | 11.0% | 6.7% | +12.5% | +3% / +98% |
| CERSCerus Corp | 430.2 m | — | -10.7% | -2.9% | +16.1% | +21% / +32% |
| BWAYBrainsway Ltd. | 415.5 m | 212.2 | 5.6% | 7.1% | +29.0% | +21% / +238% |
| TMCITreace Medical Concepts, Inc. | 271.8 m | — | -72.0% | -29.0% | +1.6% | +40% / −52% |
| ANIKAnika Therapeutics, Inc. | 258.7 m | — | -2.7% | -3.1% | −5.9% | +96% / −12% |
| UTMDUtah Medical Products, Inc. | 226.2 m | 21.7 | 8.8% | 29.0% | −5.8% | +26% / −16% |
| LUCDLucid Diagnostics Inc. | 79.3 m | — | -556.3% | -959.8% | +8.3% | −63% / −74% |
| ICCMIceCure Medical Ltd. | 50.4 m | 2.9 | -188.8% | -445.6% | +2.7% | −97% / −98% |
| MDAISpectral Ai, Inc. | 44.4 m | — | — | -65.5% | −33.6% | −30% / −53% |
1- and 3-year price returns: for MDAI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Spectral AI is an artificial intelligence company developing the DeepView System, a predictive diagnostic tool for wound healing with a focus on burns. Following FDA De Novo classification in May 2026, the company is preparing for its first commercial sales, while its current revenue comes almost entirely from U.S. government contracts and research revenue has declined, making the transition to commercialization decisive. Guidance for 2026 points to revenue of about 18.5 million USD 3.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Dependence on government fundinghigh
Revenue comes almost entirely from contracts with government agencies, and a decline in them could seriously affect the financial position 2.
- Limited liquidityhigh
Cash on hand is low, and the company depends on credit and additional financing to sustain operations 3.
- Delay in commercial salesmedium
First sales are targeted for year-end 2026, and delays could push back expected revenue 3.
- Pressure on marginsmedium
Cost-share provisions and launch pricing could reduce gross margins during the launch period 23.
- Supply chainlow
Dependence on contract manufacturers and a concentration of suppliers could lead to delays or cost increases 2.
Investment thesis
What would need to be true (bull case)
- The FDA authorization of May 2026 could turn the company from a research-focused one into one with commercial sales, if first deliveries follow the schedule 3.
- Its proprietary clinical database and the absence of comparable products could support a durable market position 1.
- BARDA funding provides a base for the next development and procurement phases 23.
What would break the thesis
What to watch
- First commercial sales of the DeepView System in the U.S.year-end 2026
- Achievement of the revenue guidance of about 18.5 million USD2026
- Trend in gross margin and BARDA cost-share provisionsQ3 2026
- Results of the triage and treatment outcome studyQ4 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Spectral AI, Inc. is an artificial intelligence company focused on predictive medical diagnostics. Its DeepView System combines a multispectral imaging component that captures tissue invisible to the naked eye with the AI-Burn software, which gives a binary prediction of a wound's capacity to heal 1. The company operates in one segment and concentrates its efforts on research and development, mainly for the burn indication 12.
The company has not yet generated product revenue. Its revenue comes almost exclusively from government contracts, especially from BARDA, part of the U.S. Department of Health and Human Services, and from other Department of Defense funding 12. The BARDA PBS contract, worth up to 150.0 million USD, supported clinical validation and the De Novo submission to the FDA 2.
The anticipated business model combines a SaaS component, with a software licensing fee covering maintenance, image hosting and access to algorithm updates, with a directly sold imaging device. Pricing is expected to be set per country and site of service 12.
Segments
Market context
The company estimates that over 57,000 clinical sites in the United States could host the technology, and over 20,000 across the UK and EU 1. The size of the market depends on whether the first commercial sales, scheduled for year-end 2026, are achieved 3.
Target customers are burn centers, trauma centers and emergency departments, and the claimed advantage is day-one diagnosis, which could shorten hospital stays 1. The company has also cited estimated cost savings per hospital stay 1.
Trends
- FDA authorization and the move to commercializationtailwind
The De Novo authorization of May 2026 opens the path to first sales in the U.S., which could move the company from one dependent on funding toward one with commercial revenue 3.
- Declining government contract revenueheadwind
As work under the BARDA PBS contract winds down, research and development revenue falls, and the company bears part of its development costs 3.
- Pressure on marginsheadwind
Gross margin fell in the second quarter of 2026 because of cost-share provisions, and launch pricing could compress margins further 23.
- Institutional interest and financingmixed
The Avenue Capital credit facility and government funding provide non-dilutive capital, but reliance on these sources remains an important factor 3.
Competitive position
The company says there are no comparable digital wound healing predictive products that give clinicians an objective, immediate AI-based assessment of healing potential 1. Indirect competition comes from standard clinical methods that rely on subjective assessment and weeks of observation 1.
According to the company, its principal barrier to entry is its clinically validated database of more than 340 billion pixels of image data 1.
- Standard clinical assessment of burns
Subjective clinical assessment followed by observation over several weeks, described by the company as the main alternative 1.
- Advanced wound care products and surgical interventions
Options clinicians choose after the initial assessment, without an objective predictive tool 1.
- Other medical imaging instrument makers
The sources do not name competitors; the company only states that no comparable products are cited.
- Portable military diagnostic tools
Possible competition for the portable variant aimed at military and emergency settings 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report15 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report12 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report11 Aug 2026
- Current report08 Jul 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report01 Jun 2026Shareholder vote · Regulation FD disclosure · Financial statements and exhibits
- Current report26 May 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report13 May 2026
- Current report22 Apr 2026Departure or appointment of officers · Financial statements and exhibits
- Proxy statement16 Apr 2026
- Current report08 Apr 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Spectral AI, Inc. · 25 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Spectral AI, Inc. · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Spectral AI, Inc. · 12 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.